Robert K. Massie Jr, PhD, MA, of the Society for Progress, was born with severe factor VIII hemophilia in August 1956. He contracted HIV in 1978 and later hepatitis C, both from contaminated blood products.
Robert K. Massie Jr, PhD, MA, of the Society for Progress, has been an Episcopal minister, a professor at Harvard Divinity School, and a nonprofit CEO, specializing in environmental questions. He was born with severe factor VIII hemophilia in August 1956 and contracted HIV in 1978, later also hepatitis C (hep C), from contaminated blood products.
Transcript
What age-related factors should patients be aware of as they live longer with any, or all, of these conditions?
Well, I think we're in unknown territory. In many ways, obviously, each of these illnesses had a very high mortality factor, at one point or another.
When I was born with hemophilia, the life expectancy—which was an average—was in the early 20s. Some people died as children, some people made it into adulthood, but it was a volatile and very painful illness, as many people may know. At least that was before you could treat the joint bleedings before they became severe and immobilized you and put you into terrible pain.
So I'm just getting older now. I have the problems of an older man. You know, skin and hearing and sleeping and all that kind of fun stuff that happens to you when you get older. And then as far as the other elements, right now I am not walking because I've had 7 or 8 surgeries on my left knee. And so I walk with a crutch or cane, but mostly with the crutch.
And then as far as HIV, or hep C, we really don't know. The HIV presumably can be controlled and suppressed between the combination of my immune system and now the medications that I now finally am on. And the reason I'm on those is because to get a new liver, they had to suppress my immune system that had been doing so well against HIV. So they thought, “Okay, we're going to have to slow down this powerful immune system, so now we'll give you the heart drugs.”
So I think we just don't know how normal a normal life expectancy I might have. I mentioned I'm 64, and I seem to be doing pretty well. But any number of things could start to break down or fail. So you know, the positive side of survivor things is that you might find yourself older, and you don't know what's gonna happen next. But who knows what's gonna happen next? And I'm kind of used to living with pretty big uncertainties over my head.
Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS
April 11th 2025Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More